News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Arno Therapeutics Reports Progress in Development of Clinical Biomarkers to Support Treatment of Breast Cancer With Onapristone



11/9/2012 11:25:05 AM

FLEMINGTON, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc. (OTCBB: ARNI) today reported progress in its clinical biomarker program to develop a companion diagnostic with onapristone in the treatment of breast and other cancers. Onapristone is the company’s investigational progestin receptor antagonist that has demonstrated anti-tumor activity in preclinical and clinical studies of hormone-dependent tumors.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES